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Case report 
A 73-year-old man with a 30-pack-year history of  smok-
ing had quit smoking six years ago. He had been admitted 
to a hospital for exacerbation of  chronic obstructive pul-
monary disease. A chest CT was done to rule out pulmo-
nary embolism. The CT scan did not reveal any pulmonary 
embolism, but it demonstrated a solid SPN in the right up-
per lobe. The 9-mm SPN (that is, the average of  the largest 
and perpendicular transverse diameters) had somewhat 
spiculated contours. FDG PET/CT was performed three 
months later to characterize the lesion. The then 11-mm 
SPN showed only minimal FDG uptake (Fig 1, A and B), 
with a maximum standardized uptake value of  1.7 (max 
SUV). This suggested a benign lesion. At followup CT six 
months later, the SPN had grown from 11 mm to 12 mm. 
The patient was re-examined by FDG PET/CT five 
months later to exclude malignancy. The SPN was now 
FDG avid and its size was 14 mm (Fig. 1, C and D). The 
max SUV was 12.7, consistent with a malignant disease. 
Whole-body FDG PET/CT did not reveal any other hy-
permetabolic lesions, and right upper lobectomy was per-
formed. Histological examination demonstrated a solid 
adenocarcinoma (gradus III). 
Discussion
FDG PET/CT has been proposed to be used routinely 
in the diagnostic workup of  patients with a SPN (1). For 
this purpose, FDG PET/CT has been found to be both 
accurate and cost-effective (2). An SUV cutoff  of  2.5 is 
commonly used to differentiate benign nodules from ma-
lignant ones, as initially suggested by Patz et al (3). All his-
tological types of  cancer may give rise to pulmonary nod-
ules, but adenocarcinomas are the most frequent (4). Ade-
nocarcinomas of  the lungs have become the most common 
lung cancers (5, 6). In FDG PET studies, false-negative 
results can occur, most frequently in association with ade-
nocarcinoma in situ (formerly bronchioloalveolar carci-
noma), carcinoids, well-differentiated adenocarcinomas, 
and tumors less than 1 cm in diameter (7, 8). There are 
widely varied subtypes of  lung adenocarcinomas (5, 9), and 
as they grow they may undergo mutations (10, 11). In the 
present case, the increased glucose metabolism in the Son 
can be attributed to a change in the histopathologic sub-
type or molecular features of  the SPN. The 3-mm increase 
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in size of  the SPN cannot explain the increase in FDG up-
take, and it is of  note that the effect of  respiratory motion 
blur is small in the upper lobe. 
In risk populations, the prevalence of  lung cancer among 
nodules measuring more than 10 mm varies between 30 
and 80% (12). Even though the negative predictive value of 
FDG PET/CT is high (13), SPNs with no-to-faint FDG 
uptake should be followed up, because the molecular biol-
ogy of  lung cancers is highly complex (5). Solid SPNs that 
remain unchanged on a followup CT after two years are 
unlikely to be malignant and do not require any further 
investigations (14). Recently, the Fleishner Society pub-
lished recommendations for the management of  subsolid 
SPNs detected at CT (15). These recommendations are 
more varied than the original Fleichner Society guidelines 
for the solid SPNs (14).
In conclusion, SPNs with no-to-faint tracer uptake on a 
FDG PET/CT should be followed up to confirm a benign 
diagnosis. CT is useful for this purpose, due to its conven-
ience and low cost.
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Figure 1. 73-year-old man with solitary pulmonary nodule. FDG 
PET/CT images at baseline (A and B, arrows point to the SPN) and 
corresponding images after a followup period of 11 months (C and 
D).
